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Abstract
Background: Similar to human breast cancer mammary tumors of the female dog are commonly associated with
a fatal outcome due to the development of distant metastases. However, the molecular defects leading to
metastasis are largely unknown and the value of canine mammary carcinoma as a model for human breast cancer
is unclear. In this study, we analyzed the gene expression signatures associated with mammary tumor metastasis
and asked for parallels with the human equivalent.
Methods: Messenger RNA expression profiles of twenty-seven lymph node metastasis positive or negative canine
mammary carcinomas were established by microarray analysis. Differentially expressed genes were functionally
characterized and associated with molecular pathways. The findings were also correlated with published data on
human breast cancer.
Results: Metastatic canine mammary carcinomas had 1,011 significantly differentially expressed genes when
compared to non-metastatic carcinomas. Metastatic carcinomas had a significant up-regulation of genes associated
with cell cycle regulation, matrix modulation, protein folding and proteasomal degradation whereas cell
differentiation genes, growth factor pathway genes and regulators of actin organization were significantly down-
regulated. Interestingly, 265 of the 1,011 differentially expressed canine genes are also related to human breast
cancer and, vice versa, parts of a human prognostic gene signature were identified in the expression profiles of the
metastatic canine tumors.
Conclusions: Metastatic canine mammary carcinomas can be discriminated from non-metastatic carcinomas by
their gene expression profiles. More than one third of the differentially expressed genes are also described of
relevance for human breast cancer. Many of the differentially expressed genes are linked to functions and
pathways which appear to be relevant for the induction and maintenance of metastatic progression and may
represent new therapeutic targets. Furthermore, dogs are in some aspects suitable as a translational model for
human breast tumors in order to identify prognostic molecular signatures and potential therapeutic targets.
Background
Canine mammary tumor (CMT) is the most common
cancer among female dogs and often becomes fatal due
to the development of distant metastases [1-3]. Metasta-
sis to the regional lymph node is an early step in metas-
tasis and one of the most important prognostic factors
in the diagnosis of CMT, a criterion that is also valid
for human breast cancer [4,5]. Lymph node metastases
of CMT are usually followed by the development of dis-
tant metastases, mainly in the lung, ultimately leading to
the death of the dog [6]. However, knowledge of the
molecular mechanisms contributing to lymph node and
distant metastasis is still fragmentary. Despite numerous
studies on this issue, significant metastasis-associated
and predictable expression patterns of single genes have
not been identified in CMT as yet [7-9]. Global gene
expression profiles that compare metastasizing versus
non-metastasizing CMT are unavailable whereas several
studies on human breast cancer found significant metas-
tasis associated expression profiles. The latter studies
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which are related to the development of lymph node
and distant metastases and worse prognoses [10-13].
The available studies on global gene expression in CMT
compared normal mammary gland, benign and malig-
nant tumors with unknown lymph node status and clini-
cal follow-up [14,15]. The authors reported that the
gene expression profiles of CMT include a gene expres-
sion signature associated with neoplastic transformation.
Furthermore, comparison of canine and human expres-
sion profiles disclosed an overlap of deregulated genes
in human and canine mammary tumors [15]. Generally,
clinical and molecular features of human and canine
bear a likeness in several aspects. Both malignancies are
the most common cancer of the female, lymph node
metastases indicate a poor prognosis, the hormonal sta-
tus influences the development of CMT and estrogen
receptor (ER), progesterone receptor (PR) and ERBB2
expression patterns do influence the overall survival rate
[1,16-18].
The aim of this study was the identification of gene
expression signatures in primary CMT that are asso-
ciated with early lymph node metastasis. Global mRNA
expression profiles obtained from metastatic versus non-
metastatic CMT cases were compared and differentially
expressed genes were analyzed for their function and
their role in pathway activation. Moreover, mining in
published literature revealed interesting overlapping fea-
tures when compared to data derived from gene expres-
sion profiles of metastatic human breast carcinomas.
Methods
Tissue samples
Thirteen simple mammary carcinomas with invasive
growth and lymph node metastases at the time of tumor
resection and 14 simple carcinomas without lymph node
metastases were included in the study (Table 1). Com-
plex carcinomas were excluded from the study to avoid
differences in gene expression levels due to differences
in mesenchymal/epithelial ratio in the different tissues.
None of the patients had a history of progestin treat-
ment or radiographically detectable pulmonary metas-
tases at the time of tumor resection. Distant metastases
as the cause of death were determined postoperatively
by radiographic detection of metastases (nos. 1-11) or
necropsy (nos. 12 and 13). Selection criteria for carcino-
mas without lymph node metastases included an inva-
sive growth, a negative lymph node status, a histological
grade III and a minimal tumor diameter above the aver-
age of the lymph node positive tumors (> 2.42 cm). All
animals with non-metastatic carcinomas had a overall
survival rate of over 24 months except animal no. 22
which developed radiographic detectable lung metas-
tases 8 months after surgery.
The experimental research reported in the manuscript
has been performed with the approval of animal welfare
authorities and the ethical committee of the Freie Uni-
versität Berlin. Surgical excision of tumour biopsies was
part of the tumour treatment according to the state of
the art treatment and solely to improve the animals wel-
fare. Furthermore, the animals were under full anaesthe-
sia and not exposed to any additional manipulation due
to the inclusion in this study. All animal owners
received and approved an informed client consent form.
Tissue specimens were fixed in neutral-buffered 4% for-
malin or snap frozen in liquid nitrogen within 15 minutes
after resection and stored at -80°C until further use. For-
malin fixed tumor tissue samples were routinely
embedded in paraffin and sections of 2-μmw e r es t a i n e d
with hematoxylin and eosin. Tumor and lymph node
histologies were evaluated independently by two board-
certified pathologists, following the criteria of the WHO
classification of canine mammary tumors and the Notting-
ham grading system [19,20]. All 27 tumors were simple
carcinomas and characterized by an invasive, mostly solid
growth pattern, marked cellular pleomorphism, anisokar-
yosis and 3 or more mitotic figures per high power field.
Immunohistochemistry
Oestrogen receptor alpha (ER), ERBB2 expression was
immunohistochemically determined using the ABC-
method. In brief, monoclonal mouse anti-human ER
specific antibody (1:1000, clone CC4-5, Novocastra,
Wetzlar, Germany) and rabbit polyclonal anti-human
ERBB2 specific antibody (1:150, cat. no. A0485, Dako,
Hamburg, Germany) were diluted in Tris-buffered saline
(TBS, 50 mM, pH 7.6) and incubated at 4°C overnight
after a blocking step with 50% goat serum in TBS for 30
min at room temperature. Polyclonal goat anti-rabbit
IgG (1:200; Vector, England, BA1000) and goat anti-
mouse IgG (1:200; BA9200, Vector, Burlingame, USA)
were used as secondary antibody. Diaminobenzidine tet-
rahydrochloride (D8001, Sigma Aldrich, Munich, Ger-
many) was used as chromogen and slides were
counterstained with hematoxylin (Merck). Normal
canine and human mammary gland were used as posi-
tive tissue controls. ER and ERBB2 immunolabeling was
evaluated in 10 random 200× magnification fields.
Tumors were defined as ER or ERBB2 positive if more
than 10% of the cells stained positive with the respective
antibody.
Macrodissection of tumor samples and RNA isolation
Macrodissection was performed on all tumor specimens
to ensure high tumor cellularity. Only sections with
more than 70% carcinoma cells were included in the
study as shown by digital image analysis (Scanscope T3,
A p e r i o ,V i s t a ,U S A ;Z e i s sA x i o v i s i o n ,J e n a ,G e r m a n y ) .
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into 300 μl of lysis buffer (NucleoSpin RNA; Macherey
& Nagel, Dueren, Germany) and homogenized (Precel-
lyse 24, Bertin Technology, France). RNA was extracted
and purified using a commercial system (NucleoSpin
RNA; Macherey&Nagel, Düren, Germany). The RNA
quality was controlled using the BioAnalyzer (Agilent
Technologies, USA) and only high quality RNA (RIN
>8) was used for microarray analyses. For reverse tran-
scription a commercial kit (Iscript cDNA synthesis Kit,
Biorad, Germany) was used. 100 ng of total RNA of
each sample were used for reverse transcription of each
tissue sample and the reactions were performed exactly
according to the manufacturers instructions. cDNA was
stored in low adhesion tubes at -20°C.
Microarray analyses
Affymetrix GeneChip hybridization (Canine Genome 2.0
Array) was performed with 2 μg total RNA according to
the manufacturer’s recommendations. The chips were
stained and washed with the GeneChip Fluidics Station
450 and visualized on an Affymetrix GeneChip Scanner
3000. Microarray data were deposited at the Gene
Expression Omnibus data repository under the number
GSE20718: (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=bbwvhacsemokkfq&acc=GSE20718)
Quantitative RT-PCR (qPCR)
Quantitative PCR was used to validate array gene
expression data. To this end, established qPCR assays
for eight genes that were identified in the metastatic
gene signature were used to compare mRNA expression
levels in metastatic and non-metastatic tumors. Primer
sequences, product length and sequence accession num-
bers for the PCR assays for AURKA, ALOX12, BMP6,
ERBB4, HEPACAM2, IGFR2, RAD51, TGFBR3 and the
housekeeper genes A5B, HPRT and RP32 mRNA
expression levels were used before [17,21-24] and are
Table 1 Tumors, lymph node status and histologic and immunohistochemical features of metastatic and non-
metastatic canine mammary carcinomas
Dog Breed Age in
years
Histologic
Grade
Tumor size
(cm)
Affected lymph
node
Postoperative overall survival
(months)
ERa ERBB2
1 American Pittbull 9 Grade III 3 Inguinal 8 - +
2 Bobtail 10 Grade III 3 inguinal 6 - +
3 Rottweiler 10 Grade III 3 inguinal 6 - +
4 Dachshund 13 Grade II 2 inguinal 3 - +
5 Bavarian Mountain Dog 13 Grade III 5 inguinal 8 - +
6 Golden Retriever 11 Grade III 1 inguinal 5 - -
7 12 Grade II 1 axillary 2 - +
8 Pudel 16 Grade II 3 inguinal 2 - -
9 West Highland White
Terrier
16 Grade II 0.5 inguinal 3 - +
10 French Bulldog 15 Grade III 1 inguinal / - +
11 Mixed Breed 16 Grade II 3 inguinal 9 - +
12 Beagle 11 Grade II 4 inguinal 1 - +
13 Mixed Breed 9 Grade III 2 inguinal / - +
14 Mixed Breed 12 Grade III 4 - >24 - +
15 Dalmatian 10 Grade II 3 - >24 - +
16 Irish Setter 9 Grade II 3 - >24 - +
17 Labrador 11 Grade III 3 - >24 - -
18 Soft coat. wheaten
Terrier
12 Grade III 4 - >24 - +
19 Mixed Breed 11 Grade III 3 - >24 - +
20 German Short Hair 12 Grade III 15 - >24 - +
21 Poodle 11 Grade II 3 - >24 - +
22 Mixed Breed 15 Grade III 7 - >8 - +
23 Miniature Pinscher 13 Grade II 2 - >24 - +
24 Mixed Breed 11 Grade III 9 - >24 - +
25 Great Dane 10 Grade III 7 - >24 - +
26 Mixed Breed 9 Grade III 3 - >24 - +
27 Mixed Breed 13 Grade III 7 - >24 - +
WHWT: West Highland White Terrier.
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Page 3 of 11describe in Additional file 1. Each qPCR reaction had a
20 μl reaction volume containing 5 μl cDNA corre-
sponding to 100 ng input RNA, 500 nM of each forward
and reverse primer, 12.5 μl of the Maxima Sybr Green/
Rox qPCR Master Mix (Fermentas, Germany) contain-
ing 2.5 mM Mg
2+ and 5 mM dNTP. Tubes and lids
were purchased from Fermentas (Germany). Cycling
parameters for all assays were, 95°C for 10 min, 95°C for
30 sec, 58°C for 60 sec, 72°C for 30 sec for 40 cycles.
Melting curve ranged from 58°C to 95°C and was read
every 0.2°C and hold for 2 sec. The cDNA of all samples
were amplified on the same plate for every primer pair
to ensure equal amplification conditions. Specificity of
amplification products was confirmed by melting curve
and sequence analyses. For each sample, results were
documented as cycle threshold (CT) set to 100 relative
fluorescence unit values of background subtracted qPCR
fluorescence kinetics by using the MX Pro Stratagene
analysis software, applying the adaptive baseline, amplifi-
cation based threshold and moving average algorithm
enhancement. Relative expression of the target gene
(TG) was calculated using a comparative ΔCT-method
with multiple housekeepers as previously described
[25-27]. The housekeeper genes used were selected from
a panel of reference genes (RG) according to the GeN-
orm algorithm[28]. Data are presented as fold change in
gene expression level of the gene of interest (GOI) in
lymph node-positive carcinomas (LN+) normalized to
the housekeepers and to the similarly normalized GOI
expression levels in lymph node-negative carcinomas
(LN-). Significance (p < 0.05) of differential gene expres-
sion was tested using Shapiro-Wilk-test and t-test.
Data analysis
Affymetrix CEL files were imported into Partek Genomic
Suite Software (Version 6.4, Partek Inc., St. Louis, USA)
and processed by the implemented gcRMA workflow
(median polish probe set summarization, RMA back-
ground correction, quantile normalization). Differences
in gene expression between samples with and without
metastases were analyzed by ANOVA and false discovery
rate was controlled by using the q-value method. Differ-
entially expressed genes were selected by applying a filter
of q < 0.001 and a fold-change of >1.7 in both directions.
Unnamed genes were excluded from the list. Hierarchical
clustering of the samples and genes was conducted using
Pearson correlation and complete linkage.
To supplement the gene annotations of the differen-
tially expressed genes with functional information,
BLAST search and Affymetrix-provided human to
canine microarray comparisons were used to map
canine genes to their human equivalents as has been
shown before [29]. Using the human equivalents as tem-
plates, the DAVID database was queried for gene
ontology information [30]. To study enriched functional
gene families and functional annotation, all down-
regulated and all up-regulated genes were submitted
separately to DAVID. In the case of redundant probe
with a fold change in the same direction only the probe
set with the highest fold change was included in further
analysis. Selection criteria for DAVID included a med-
ium stringency, ≥ 4 probes within a cluster and an
enrichment factor >1.3. In case of multiple appearances
of similar gene families or functional annotation terms,
the cluster with the higher enrichment factor was
selected. Reported associations between the differentially
expressed genes and human breast cancer were deter-
mined using the MEDGENE database [31], entering the
search term: ‘breast neoplasms’.
The GenMAPP software was used for pathway analy-
sis [32]. Analyses of up- or down-regulated gene sets
were performed independently. Quality criteria for path-
way selection included more than 3 genes, z-score of
|>2| and p < 0.05.
Results
Immunohistological phenotype of the tumors
All lymph node positive and lymph node negative
tumors were ER negative. In addition, 11/13 lymph
node positive tumors and 13/14 lymph node negative
tumors were ERBB2 positive.
Identification of differentially expressed genes
Comparison of the global expression of canine mam-
mary carcinomas with or without lymph node metastasis
revealed 1011 differentially expressed genes, 744 genes
of which were up-regulated metastatic carcinomas
whereas only 267 genes were down-regulated (1.7× fold
change, false discovery rate q < 0.001, Additional file 2).
With the exception of two cases (dogs no. 14, 22), these
genes were able to clearly separate the two tumor
groups by means of two-dimensional hierarchical clus-
tering (Figure 1). Interestingly, one of the tumors (no.
22) developed radiographic detectable lung metastases 8
months postoperatively. However, the other case (14)
did not develop metastases during a 24 month clinical
follow-up. qPCR confirmed significant expression differ-
ences for all seven of the eight genes analyzed (Table 2).
Up-regulation of cell cycle and DNA-damage repair genes
in metastatic canine carcinomas
Functional analysis of the metastasis-associated genes
identified an up-regulation of 93 cell cycle associated
genes with functions in cell cycle progression (Table 3).
Interestingly, the 13 cell cycle checkpoint genes and 27
DNA-damage repair genes in the gene list were exclu-
sively up-regulated and only one of the 6 cyclin genes
was down-regulated (Table 3). 49 genes associated with
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protein folding, ubiquitin dependent proteins and prefol-
dins, suggesting an increased biosynthesis of the cells.
Furthermore, anti-apoptotic and pro-apoptotic genes,
members of the RAS signaling cascade were up-
regulated (Table 4). Interestingly, transcription factors and
methyltransferases were significantly enriched in both up-
regulated and down-regulated gene lists indicating that
the metastatic phenotype is associated with a different
equilibrium of gene activation and deactivation (Table 4).
Down-regulation of growth factor receptor pathways and
cell differentiation genes in metastatic canine carcinomas
39 genes with receptor activity were up- and down regu-
lated in metastatic tumors (Table 4, 5). However, trans-
membrane tyrosine kinase receptor genes were
Figure 1 Two dimensional cluster analysis of metastatic versus non-metastatic canine mammary tumors. Two of the lymph node
metastasis-negative carcinomas were adjoined to the metastatic tumor cluster. One of these animals (no. 22) developed lung metastases 8
months after initial surgery despite negative lymph-node status.
Table 2 Confirmation of cDNA-Array data by quantitative RT-PCT
Gene Mean fold change in metastatic carcinomas by qPCR Mean fold change in metastatic carcinomas by microarray
AURKA 2.5 (0.52)* 5.9
ALOX12 0.6 (0.11)* 0.4
BMP-6 2.4 (0.97)* 4.4
ERBB-4 0.4 (0.09)* 0.4
HEPACAM2 0.2 (0.05)* 0.01
IGFR2 0.6 (0.11) 0.4
RAD51 2.4 (0.67)* 4.7
TGFBR-3 0.41 (0.90)* 0.2
*Difference between mean expression levels significant (p < 0.05).
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static carcinomas (Table 5). Specifically, genes of growth
factor signaling pathways epidermal growth factor
(EGF), transforming growth factor-beta (TGFB), fibro-
blast growth factor (FGF), hepatocyte growth factor
receptor (MET) and insulin-like growth factor (IGF)I
and II were preferentially down-regulated in the meta-
static tumors. Besides their growth stimulatory effects,
EGF, TGF and FGF signaling also induces cell differen-
tiation in mammary epithelial cells and a down regula-
tion of these pathways and associated proteins has been
described before [24,33-37].
In line with this changed receptor signaling in meta-
static carcinomas is therefore the de-regulation of sev-
eral genes associated with cell growth regulation and
cell differentiation in the metastatic tumors (Table 5).
Interestingly, statistical analysis by DAVID gene ontol-
ogy identified a significant enrichment of cell differentia-
tion genes only in the list of down-regulated genes
(Tables 4).
Cell-cell adhesion and matrix modulation genes are
differentially expressed in metastatic tumors
It is commonly accepted that metastasis requires loss of
cell-cell adhesion and expression of extracellular matrix
modulators by the tumor cells. We, therefore, specifically
screened the gene list for modulators of the extracellular
matrix, cell adhesion and angiogenesis genes. Statistical
analysis found no significant enrichment of matrix mod-
ulator genes in the gene list (Table 4). However, three
matrix modulator genes: matrix-metalloproteinase 11,
Table 3 Up- and down-regulated cell cycle genes
Up-regulated cell cycle genes Down-regulated cell cycle genes
Cell Cycle Genes
ANAPC10, APPL1, AURKA, BIRC5, BUB3, CCDC5, CCNA2, CCNB1, CCNB2, CCNE1, CDC2, CDC27,
CDC37, CDC45L, CDC5L, CDC6, CDCA2, CDCA5, CDCA8, CETN3, CGREF1, CHAF1A, CHAF1B, CHEK2,
CKAP2, DKC1, DTYMK, ERBB2IP, ESCO2, ESPL1, EXO1, FBXO5, GADD45B, GADD45GIP1, GMNN,
GTSE1, ILF3, INCENP, IRF1, KATNA1, KIF15, KIF23, KIFC1, LIN9, MAD2L1, MCM5, MCM6, MIS12,
MRPL41, MYBL2, NCAPG, NCAPG2, NCAPH, NDC80, NME1, NOLC1, NPM1, NUF2, NUSAP1, PARD3B,
PBK, PES1, PFDN1, PIK3CB, PLK1, PPM1G, PRC1, PRMT5, PTPN11, RAD17, RAD21, RAD51, RANBP1,
RASSF1, RASSF4, B1CC1, RBL1, RPA1, SASS6, SGOL1, SMC1A, SPC24, SPC25, SPIN1, STK11, SUGT1,
TPX2, TTK, TXNL4A, UHRF1, YEATS4, YWHAQ, ZW10
BCL6, DBC1, DST, KHDRBS1, LATS1, NEDD9,
PPP2R1B, RBM5, SESN1, TARDBP,
Cell Cycle Checkpoint Genes
BIRC5, BUB3, CDC2, CDC45L, CDC6, CHEK2, GTSE1, MAD2L1, PTPN11, RAD17, SMC1A, TTK, ZW10,
Cyclin Genes
CCNE1, RBL1, CCNB2, CCNA2, CCNB1 CCNL2
DNA-Damage Repair Genes
APEX2, CHAF1A, CHAF1B, DCLRE1B, ESCO2, EXO1, FEN1, GADD45B, GADD45GIP1, GEN1, GTF2H3,
NSMCE2, NUDT1, POLD3, RAD17, RAD21, RAD51, RAD51C, RFC3, RPA1, SMC1A, SMC5, TOPBP1,
TYMS, UBE2N, UHRF1, UNG
Table 4 Enriched functional gene classes in the
differential expression profile of metastatic canine
mammary tumors
Functional gene class Gene
number
Enrichment
factor
up-regulated genes
M-phase 52 17.49
DNA replication 29 6.72
Protein folding 32 6.34
Transcription factors 48 6.21
RNA processing 50 5.99
Apoptosis 10 5.98
Mitochondrion 59 5.96
Cell cycle checkpoint 14 4.09
DNA damage response 30 3.52
Ubiquitin-pathway 13 2.56
DNA-replication initiation 7 2.05
Methyltransferases 15 1.95
RAS-signalling 5 1.71
Prefoldins 4 1.62
Transcription repressors 13 1.32
down-regulated genes
Transcription factors 55 3.62
mRNA processing 11 3.45
Muscle contraction 10 2.86
Transcription regulation 41 2.36
Cell growth regulation 10 2.03
Methyltransferases 6 1.75
Cell differentiation 54 1.58
Transmembrane tyrosine kinase
receptors
12 1.33
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inhibitor E1, were up-regulated in metastatic tumors
(Table 6) and this is in agreement with earlier observa-
tions in human breast cancer [38-40]. Similarly, cell
adhesion genes were also not significantly enriched in the
gene list. However, the 20 adhesion and focal adhesion
complex genes present in the differential gene list were
predominantly down-regulated, like HEPACAM2, EMI-
LIN1, PCDHGC3 and ASAM but some adhesion genes
were also up-regulated, like ICAM2 and the ITGA4
(Table 6). A similar expression pattern for several of
these genes has been described for human breast cancer
and other cancer types before (Table 6) [23,41-44].
Finally, analysis of the gene list disclosed no significant
enrichment of angiogenesis genes. The 7 angiogenesis
genes present in the list were also predominantly down-
regulated (e.g. NRP1, JMJD6, CYR61, FGFR1) and again
the impact of these genes on the carcinogenesis of
breast cancer cells has been described [36,45,46].
Comparison with human breast cancer expression profiles
The identified metastasis-associated expression profile of
canine mammary tumors has several significant overlaps
with expression profiles of metastatic human breast can-
cer. Literature mining by Medgene disclosed that 25% of
the canine gene list has been cited in association with
human breast cancer before. However, the mining
approach by Medgene is based on information presented
in the abstract of the articles and not complete gene
expression profiles [31]. It is therefore likely that a com-
parative meta-analysis of gene expression profiles will
identify additional overlapping gene expression patterns.
The overlapping genes are mostly associated with cell
division, cell growth, kinase activity, translation, DNA
integrity checkpoint and transcription regulation.
GenMapp pathway analysis identified a marked over-
lap of deregulated pathways in the canine metastatic
profile and a recent meta-analysis on metastasis-
associated gene expression profiles (Table 7) [10]. All 5
significantly up-regulated pathways were Identical to
human breast cancer the cell cycle, G1 to S control reac-
tome and DNA replication reactome pathways were
up-regulated, whereas striated muscle contraction and IL-
6 pathways were significantly down-regulated. (Table 7).
Furthermore, comparison with the van’t Veer 70 gene
prognostic signature which reliably identifies human
breast cancers with metastatic potential also found a sig-
nificant overlap [13]. However, only 34 of the 70 genes
a r ep r e s e n to nt h ec a n i n eg e n ea r r a yb u t2 3( 6 8 % )o f
these genes were included in the metastatic gene
Table 5 Up- and down-regulated receptors genes
Up-regulated receptor genes Down-regulated receptor genes
Receptors
CD300LF, CRLF3, F2RL1, FKBP3, GOSR2, HYAL2, IL10RB, ITGA4, JMJD6,
KIF15, LBR, MED30, PFDN6, RNF139, SIVA1, TFRC, TREM1, ZNHIT3
EPHB1, EPHB3, ERBB4, FGFR1, FKBP, GIT2, GPR116, IGF2R, MET, NISCH,
NRP1, NPR2, NRXN1 NTRK2, PRKCZ, PTPN2, TGFBR3, THRB, TNFRSF1B,
TNFRSF21, TNPO3
Transmembrane Receptors with Tyrosine Kinase Activity
EPHB1, EPHB3, ERBB4, FGFR1, IGF2R, MET, NRP1, NTRK2, TGFBR3,
G-Protein Coupled Receptors
F2RL1, SLC26A6 GPR116, NPR2
Cell Differentiation Genes
AATF, ASF1B, Bak1, BCLAF1, BID, BIRC3, BIRC5, BMP6, BNIP2, CASC5,
CASP6, CDC2, CEP57, CHEK2, CKAP2, CLN5, CNP, CSE1L, DNAJA3, DNM1L,
EIF2B2, ESPL1, FASTKD3, FBXO5, GADD45B, HRB, HSPD1, JMJD6, KATNA1,
MRPL41, MYBL2, NME1, NPM1, OPA1, PDCD10, PEX13, PLDN, PRKAA1,
PTPN11, RAD21, RB1CC1, RNF6, RNF7, SAP30BP, SFXN1, SIVA1, SKIL, SLTM,
SON, STK3, STK4, STRBP, TGM2, WHSC1L1, YWHAG
ACTN1, AFF4, ALOX12, BCL6, CATSPER1, CSPG5, DBC1, EPHB3, ERBB4,
FGFR1, FST, GATA3, MET, MYH11, NRP1, NRXN1, NTF3, NTRK2, PIK3R1,
PPP2R1B, PRKCZ, SEMA6D, SMARCA1, SOX5, SOX6, TBX19, THRB,
TNFRSF1B, TNFRSF21, TSG101, ZBTB16
Table 6 Up- and down-regulated matrix modulator, cell adhesion and focal adhesion complex genes
Up-regulated genes Down-regulated genes
Matrix Modulators
MMP11, SERPINE1, CTSL2
Cell adhesion
DST, ICAM2, ITGA4, ITGB1BP1,
LBR
ACTN1, ALOX12, ASAM, BCL6, CHAD, COL16A1, CYR61, DST, EMILIN1, HEPACAM2, MIA3, NEDD9, NRP1, NRXN1,
PCDHGC3
Focal Adhesion
PTK2 ACTN1, BIRC3, CHAD, COL2A1, MET, MYLK, PIK3R1
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prognostic gene expression patterns may exist in canine
mammary tumors (Table 8).
Discussion
In the present study we identified a gene expression
profile in CMT that is associated with early metastatic
spread to the lymph nodes and is able to discriminate
carcinomas with similar histological features but diver-
gent metastatic potential. The differential expression
profile contains several enriched functional gene classes
and has significant overlaps with expression profiles of
metastatic human breast cancer.
The similarities found between canine and human
mammary tumors in terms of increased proliferation,
altered cell differentiation status and decreased cell adhe-
sion were also confirmed by Medgene literature mining.
Approximately 25% of the deregulated genes in meta-
static canine carcinomas have been cited in association
with human breast cancer. In this subset of cited genes, a
significant enrichment of genes associated with cell cycle
regulation, protein kinases, DNA integrity checkpoint
and protein metabolism was observed. In addition, more
than 60 percent of the van’t Veer 70-gene prognostic sig-
nature was identified in our differential gene list. It is
therefore likely that gene expression profiles may also
predict metastasis in CMT. For instance, one of the dogs
without lymph node metastases at the time of investiga-
tion developed later distant metastases. Strikingly, this
case clustered within the group of metastatic tumors
indicating that metastatic potential can be identified in
CMT before clinically and morphologically overt metas-
tases. It will be therefore of interest to compare the gene
expression profiles of lymph node negative CMT with a
comprehensive clinical follow-up to identify potential
predictive patterns similar to human breast cancer.
Generally, metastatic CMT were characterized by
increased expression of cell division genes. These findings
are identical to a recent meta-analysis on expression pro-
files of metastasizing human breast cancer which found
cell cycle and DNA replication pathways most significantly
up-regulated [10,13,47]. Unexpectedly, this expression
profile of increased proliferation was accompanied by sig-
nificantly decreased growth factor receptor expression.
Increased proliferation and malignant transformation of
most cancer types is at least in part commonly attributed
to aberrant growth factor signaling. In addition, growth
factor signaling is also a major differentiation impulse.
The decreased growth factor pathway expression in meta-
static carcinomas hence may be a possible cause for the
altered expression of cell differentiation and unlocked cell
growth regulation genes in these CMT. The dysregulation
of cell cycle control is therefore a dominant, cross species
feature metastatic mammary tumors. Common “driver”
mutations of this cell proliferation in the tumor genome of
both species are unknown at the moment. The partly
overlapping transcriptome of metastatic canine and
human carcinomas, however, indicate similar mechanisms
of mammary carcinogenesis and a suitable molecular
model character of canine mammary tumors.
Genes associated with focal adhesion and regulation of
actin cytoskeleton organization were significantly down-
regulated in metastasizing CMT. This is in agreement
with the observation that loss of cell to cell contact is a
major step in the metastatic process and has been
observed in canine mammary tumors before [48,49]. The
effect of the down-regulated pathway of actin regulation
is somewhat unclear, but disorganization of the actin
cytoskeleton is a common feature of malignant breast
cancer cells [50]. Of interest qPCR analyses confirmed
the differences in mRNA expression levels in metastatic
and non-metastatic carcinomas although the fold change
in expression difference consistently lower in the qPCR
assays when compared with microarray assays for all
eight genes analyzed. The eight genes, AURKA, ALOX12,
BMP6, ERBB4, HEPACAM2, IGFR2, RAD51, TGFBR3,
Table 7 Up- and downregulated pathways in metastatic carcinomas when and (GenMAPP analysis)
Dysregulated pathways in metastatic
canine mammary tumors
Gene number Dysregulated pathways in
metastatic human breast cancer
up-regulated pathways Ranking in a meta-analysis[1]
Cell_cycle 33 1
Cell_cycle_G1_to_S_control_reactome 22 2
DNA_replication_reactome 25 3
Tissue_embryonic_stem_cell 11 6
Proteasome degradation 7 7
down-regulated pathways
Striated_muscle_contraction 8 4
Focal_adhesion 11 /
IL-6_NetPath_18 5 6
/not present in the metastatic pathways analysis of human breast cancer
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Page 8 of 11were selected due to their description in the literature on
canine mammary tumors before[17,21-24,51]. Their gene
expression has been described metastatic carcinomas,
metastases, adenomas and normal mammary gland and
these studies showed a similar tendency of changes in
gene expression between benign and malignant canine
mammary tissue types[17,21-24,51]. Of note, a compari-
son of the proteome of the same subset of tumours did
not identify similar proteins[52].
Conclusion
In conclusion, our findings show that metastatic spread
of CMT to the lymph nodes is associated with a gene
expression profile of increased cell cycle progression,
altered cell differentiation and decreased growth factor
signaling. Furthermore, several matrix modulators and
cell adhesion genes have an altered expression in meta-
static tumor cells while angiogenesis gene expression is
not differentially regulated in metastatic and non-
Table 8 Identification of canine genes in the expression profile of metastatic CMT homologous or similar to the
70-gene prognostic signature for human breast cancer
Human genes of the 70 prognostic
gene profile (van’t Veer et al.)
Homologous genes expressed in
metastatic canine tumors
Gene family members expressed
in canine tumors
Homologous genes present on canine gene array
AP2B1 AP2B1 -
CCNE2 - CCNE1
CDC42BPA - -
CENPA CENPA -
COL4A2 COL2, 16
DCK DCK -
DIAPH3 DIAPH3 -
ECT2 ECT2 -
EGLN1 - -
ESM1 ESM1 -
EXT1 - -
FGF18 - -
FLT1 - -
GMPS - GMPS
GNAZ - -
HRASLS - -
IGFBP5 - -
LPCAT1 LPCAT1 -
MCM6 MCM6 -
MELK MELK -
MMP9 - MMP11
MS4A7 - -
NDC80 NDC80 -
ORC6L ORC6L -
OXCT - -
PECI - -
PRC1 PRC1
RAB6B - RAB10, 7L1, EPK
RFC4 - RFC2, 3
SCUBE2 - -
SLC2A3 - -
STK32 - STK3, 4, 11
TGFB3 - -
UCHL5 - UCHL3
ALDH4 - ALDH16
FAM2A - FAM13B
NMU - NMB
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Page 9 of 11metastatic CMT. Several major aspects of metastasis-
associated gene expression are therefore similar between
human and canine mammary tumors. Furthermore, the
differential expression profiles in metastatic and non-
metastatic carcinomas allow a prediction of clinical
behavior and offer several new hypotheses for molecular
pathways and networks involved in the metastatic pro-
cess of canine mammary tumors.
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